RCUS FY2025 EPS Estimate Raised by Cantor Fitzgerald

Arcus Biosciences, Inc. (NYSE:RCUS) – Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for Arcus Biosciences in a research report issued on Tuesday, March 11th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($3.65) per share for the year, up from their prior estimate of ($5.29). The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share.

A number of other equities research analysts also recently issued reports on RCUS. Bank of America reduced their price objective on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, February 19th. Morgan Stanley reduced their price target on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Finally, HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $30.25.

Arcus Biosciences Stock Down 1.4 %

Shares of RCUS stock opened at $9.57 on Thursday. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences has a 12 month low of $9.01 and a 12 month high of $19.18. The stock has a market cap of $1.01 billion, a P/E ratio of -3.04 and a beta of 1.36. The company has a 50 day simple moving average of $12.47 and a two-hundred day simple moving average of $15.01.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.17) by $0.14. The firm had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, Director Yasunori Kaneko bought 20,000 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were purchased at an average price of $10.06 per share, with a total value of $201,200.00. Following the completion of the purchase, the director now owns 28,400 shares in the company, valued at $285,704. This represents a 238.10 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Terry J. Rosen purchased 19,800 shares of Arcus Biosciences stock in a transaction dated Thursday, February 27th. The stock was acquired at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the acquisition, the chief executive officer now owns 2,554,160 shares of the company’s stock, valued at approximately $26,001,348.80. This trade represents a 0.78 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. R Squared Ltd bought a new position in Arcus Biosciences in the 4th quarter worth about $26,000. Point72 Hong Kong Ltd bought a new position in Arcus Biosciences in the third quarter worth approximately $47,000. Lazard Asset Management LLC increased its holdings in Arcus Biosciences by 3,321.3% during the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock worth $93,000 after purchasing an additional 6,078 shares during the period. US Bancorp DE raised its position in Arcus Biosciences by 2,432.0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after purchasing an additional 6,615 shares in the last quarter. Finally, Quest Partners LLC grew its position in shares of Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after buying an additional 9,408 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.